Skip to main content
Edwards Lifesciences Logo

Insights that value individuals

A heart-to-heart conversation could help protect what matters most to your patients.

A doctor with a patient looking at the tablet
A doctor with a patient looking at the tablet
A doctor with a patient looking at the tablet

Choosing tissue? Consider RESILIA tissue valves

For patients referred for surgical valve replacement, there are now three options: mechanical valves, conventional tissue valves or RESILIA tissue valves.  Include RESILIA tissue and its unique benefits in the valve selection discussion with your patients.

Test your knowledge

What is the primary cause of tissue valve failure?

Tissue with a difference. Designed to last1,2*

INSPIRIS RESILIA aortic valve
INSPIRIS RESILIA aortic valve
INSPIRIS RESILIA aortic valve
  • The primary cause of tissue valve failure is calcification.
  • The INSPIRIS RESILIA aortic valve is made with bovine heart tissue that has been preserved with a special Edwards Lifesciences technology to reduce calcium buildup.
  • Less calcium build-up could potentially allow the valve to last longer than conventional tissue valves.*

RESILIA tissue offers enhanced anti-calcification technology that will potentially allow the valve to last longer than conventional bioprosthetic valves.1,3*

*No clinical data are available that evaluate the long-term impact of RESILIA tissue treatment in patients.

The RESILIA tissue portfolio represents the culmination of years of careful, deliberate development

Built on a proven valve platform

The foundation of the INSPIRIS RESILIA valve is the PERIMOUNT valve platform, whose performance is backed by 30 years of durability data, including the largest long-term study of a bioprosthetic valve.

30 years of published clinical durability
30 years of published clinical durability
30 years of published clinical durability

PERIMOUNT valve platform

More than 40 years of real-world experience
More than 40 years of real-world experience
More than 40 years of real-world experience

PERIMOUNT valve platform

Over 200,000 implants worldwide
Over 200,000 implants worldwide
Over 200,000 implants worldwide

INSPIRIS RESILIA aortic valve

Valves with RESILIA tissue continue to show strong performance and durability in the aortic position

What does the right surgical valve mean to your patients?
What does the right surgical valve mean to your patients?
What does the right surgical valve mean to your patients?

Have patients getting ready for surgery? Get all the details you need to guide them to their best option.

Backed by a growing body of evidence

Inspiring Results
Inspiring Results
Inspiring Results
Inspiring Results
Inspiring Results
Inspiring Results

References

  1. Flameng W, Hermans H, Verbeken E, Meuris B. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg. 2015 Jan;149(1):340-
  2. Beaver T, Bavaria JE, Griffith B, et al.  Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis.  Presented at the 103rd Annual Meeting of the American Association for Thoracic Surgery, May 2023. 
  3. Bartus K, Bavaria JE, Thourani VH, et al. Structural hemodynamic valve deterioration durability of RESILIA-tissue versus contemporary aortic bioprostheses. J Comp Eff Res. 2023 Mar;12(3):e220180.

Important safety information

RESILIA Tissue Devices

Indications: INSPIRIS RESILIA Aortic Valve - For use in replacement of native or prosthetic aortic heart valves. KONECT RESILIA Aortic Valved Conduit - For use in replacement of native or prosthetic aortic heart valves and the associated repair or replacement of a damaged or diseased ascending aorta. MITRIS RESILIA Mitral Valve - For use in replacement of native or prosthetic mitral heart valves.

Contraindications: There are no known contraindications with the use of these RESILIA tissue heart valve devices.

Complications and Side Effects: INSPIRIS RESILIA Aortic Valve - Thromboembolism, valve thrombosis, hemorrhage, hemolysis, regurgitation, endocarditis, structural valve deterioration, nonstructural dysfunction, stenosis, arrhythmia, transient ischemic attack/stroke, congestive heart failure, myocardial infarction, any of which could lead to reoperation, explantation, permanent disability, and death. Additional adverse events potentially associated with the use of polyester vascular grafts in the KONECT RESILIA AVC include hemorrhage, thrombosis, graft infection, embolism, aneurysm, pseudoaneurysm, seroma, occlusion (anastomotic intimal hyperplasia), immunological reaction to collagen (shown to be a weak immunogen; infrequent, mild, localized and self-limiting), intimal peel formation, and conduit dilatation. MITRIS RESILIA Mitral Valve - Thromboembolism, valve thrombosis, hemorrhage, hemolysis, regurgitation, endocarditis, structural valve deterioration, nonstructural dysfunction, stenosis, arrhythmia, transient ischemic attack/stroke, congestive heart failure, myocardial infarction, ventricular perforation by stent posts, any of which could lead to reoperation, explantation, permanent disability, and death.

Warnings: INSPIRIS RESILIA Aortic Valve - DO NOT ADJUST THE VALVE DIAMETER BY EXPANDING THE BAND PRIOR TO OR DURING IMPLANTATION OF THE SURGICAL VALVE. The expandable band is not designed to allow for compression or expansion during implantation of the surgical valve. This will cause damage to the valve and may result in aortic incompetence. DO NOT PERFORM STAND-ALONE BALLOON AORTIC VALVULOPLASTY PROCEDURES ON THIS VALVE FOR THE SIZES 19 – 25 mm as this may expand the valve causing aortic incompetence, coronary embolism or annular rupture. Valve-in-valve sizing in the INSPIRIS valve has only been tested with specific Edwards transcatheter heart valves. Use of other transcatheter valves may result in embolization of transcatheter devices anchored within or result in annular rupture.

CAUTION: Federal (USA) law restricts these devices to sale by or on the order of a physician. See instructions for use for full prescribing information.